Peptide Protocol
Peptide Protocol
 App Store

5-Amino-1MQ: the complete guide

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in metabolic control of adipose tissue. Preclinical studies show favorable effects on body composition in animal models.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassNNMT inhibitor (small molecule)
Half-lifeApproximately 5–6 hours (preclinical data)
Typical dose50–150 mg oral once daily (research protocols)
CategoryMetabolic / NNMT
Research useObesity research, adipose metabolism
FDA statusNot FDA approved. Research use only. No approved human clinical program as of 2026.

How 5-Amino-1MQ works

NNMT methylates nicotinamide, depleting the methyl-donor pool and affecting NAD+ salvage. Inhibiting NNMT in adipocytes shifts substrate flux toward energy expenditure in preclinical models.

Typical 5-Amino-1MQ dosage

Commonly reported research ranges: 50–150 mg oral once daily (research protocols).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

Administration

5-Amino-1MQ is taken orally — no reconstitution is required. Follow the manufacturer's guidance for liquid or capsule dosing.

Half-life and administration frequency

Approximately 5–6 hours (preclinical data).

This half-life informs how often 5-Amino-1MQ is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common 5-Amino-1MQ stacks

Storage and handling

Oral, room temperature (trial formulation).

FDA and regulatory status

Not FDA approved. Research use only. No approved human clinical program as of 2026.

5-Amino-1MQ clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your 5-Amino-1MQ protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in metabolic control of adipose tissue. Preclinical studies show favorable effects on body composition in animal models.

How does 5-Amino-1MQ work?

NNMT methylates nicotinamide, depleting the methyl-donor pool and affecting NAD+ salvage. Inhibiting NNMT in adipocytes shifts substrate flux toward energy expenditure in preclinical models.

What is a typical 5-Amino-1MQ dose?

Commonly reported ranges are 50–150 mg oral once daily (research protocols). This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of 5-Amino-1MQ?

Approximately 5–6 hours (preclinical data). This influences how often it is taken.

Does 5-Amino-1MQ require reconstitution?

5-Amino-1MQ is not handled as a standard lyophilized injectable reconstitution page in this database. Follow the manufacturer, study protocol, or clinician instructions for the specific formulation.

What are the side effects of 5-Amino-1MQ?

Limited human safety data; Potential effects on methylation-dependent pathways are incompletely characterized.

Is 5-Amino-1MQ FDA approved?

Not FDA approved. Research use only. No approved human clinical program as of 2026.

Are there clinical trials for 5-Amino-1MQ?

Registered or published clinical-trial sources for 5-Amino-1MQ are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. 5-Amino-1MQ / NNMT inhibitor literature — National Library of Medicine. Primary preclinical research on 5-amino-1MQ and NNMT inhibition
  2. Kannt et al. — NNMT as a target for metabolic disease — PubMed. Foundational work on NNMT pharmacology in metabolic models
  3. NNMT inhibitor trial records — ClinicalTrials.gov. Registered studies — limited as of 2026

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.